Barely Significant
← all excerpts

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.

Lancet Oncol · 2021 · PMC8324484 · PMID 34339645

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantp<0·0001actually significant
Pooled analysis of all trials found a highly significant reduction in recurrence (RR 0·66, 95% CI 0·62 to 0·71; p<0·0001; figure 1 ) and breast cancer mortality (0·67, 0·61 to 0·73; p<0·0001; appendix p 7 ) with chemotherapy plus trastuzumab compared with chemotherapy alone.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.